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Abstract: Photochemistry is a rich source of inspiration for developing alternative methods to function-
alize proteins with drug molecules, fluorophores, and radioactive probes. Here, we report the synthesis
and photochemical reactivity of a modified diethylenediamine pentaacetic acid chelate that was deriva-
tized with a light-responsive aryl azide group (DTPA-PEG3-ArN3, compound 1). The corresponding
nonradioactive and radioactive nat/68Ga3+ and nat/111In3+ complexes of DTPA-PEG3-ArN3 were
synthesized and their physical and photochemical properties were studied to evaluate the potential of
employing this ligand system in the photochemical synthesis of radiolabeled antibodies. Photodegra-
dation kinetics revealed that irradiation with ultraviolet light (365 nm) induced rapid photoactivation
of compound 1 and the metal complexes nat/68Ga-1– and nat/111In-1–. Light-induced reactions were
complete in <100 s, with measured first-order rate constants of 0.078 ± 0.045 s–1, 0.093 ± 0.009 s–1,
and 0.117 ± 0.054 s–1 (n = 2, per species) for compound 1, natGa-1–, and natIn-1–, respectively. Photo-
chemically induced bioconjugation reactions between DTPA-PEG3-ArN3 and the monoclonal antibody
trastuzumab, as well as pre- and postconjugation 68Ga- and 111In-radiolabeling experiments, were per-
formed using either a one-pot or two-step strategy. Both approaches yielded radiolabeled trastuzumab
([68Ga]GaDTPA-azepin-trastuzumab) with average radiochemical conversions of 3.9 ± 1.0% (n = 4, one-
pot), and 10.0 ± 1.0% (n = 3, two-step). One-pot radiolabeling reactions with [111In]InCl3 produced the
corresponding [111In]InDTPA-azepin-trastuzumab radiotracer in a similar radiochemical conversion of
5.4 ± 0.8% (n = 3). Radiochemical conversions for the desired bimolecular coupling between the chelate
and the protein were comparatively low. This observation is likely caused by the high photoinduced re-
activity of the compounds and subsequent competition with background reactions. Nevertheless, access
to DTPA-PEG3-ArN3 increases the scope of photoradiochemical methods to include metal ions like In3+
that form complexes with higher coordination numbers.
DOI: https://doi.org/10.1021/acs.inorgchem.9b01802
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Photochemistry is a rich source of inspiration for developing alternative methods to functionalise 
proteins with drug molecules, fluorophores and radioactive probes. Here, we report the synthesis 
and photochemical reactivity of a modified diethylenediamine pentaacetic acid chelate that was 
derivatised with a light-responsive aryl azide group (DTPA-PEG3-ArN3, compound 1). The 
corresponding non-radioactive and radioactive nat/68Ga3+ and nat/111In3+ complexes of DTPA-PEG3-
ArN3 were synthesised and their physical and photochemical properties were studied to evaluate 
the potential of employing this ligand system in the photochemical synthesis of radiolabelled 
antibodies. Photodegradation kinetics revealed that irradiated with ultraviolet light (365 nm) 
induced rapid photoactivation of compound 1, and the metal complexes nat/68Ga-1– and nat/111In-1–
. Light-induced reactions were complete in < 100 s, with measured first-order rate constants of 
0.078 ± 0.045 s-1, 0.093 ± 0.009 s-1 and 0.117 ± 0.054 s-1 (n = 2 per species) for compound 1, natGa-
1– and natIn-1–, respectively. Photochemically induced bioconjugation reactions between DTPA-
PEG3-ArN3 and the monoclonal antibody trastuzumab, as well as pre- and post-conjugation 68Ga- 
and 111In-radiolabelling experiments were performed using either a one-pot or two-step strategy. 
Both approaches yielded radiolabelled trastuzumab ([68Ga]GaDTPA-azepin-trastuzumab) with 
average radiochemical conversions of 3.9 ± 1.0% (n = 4, one-pot), and 10.0 ± 1.0% (n = 3, two-
step). One-pot radiolabelling reactions with [111In]InCl3 produced the corresponding 
([111In]InDTPA-azepin-trastuzumab radiotracer in a similar radiochemical conversion of 5.4 ± 
0.8% (n = 3). Radiochemical conversions for the desired bimolecular coupling between the chelate 
and the protein were comparatively low. This observation is likely caused by the high photo-




Nevertheless, access to DTPA-PEG3-ArN3 increases the scope of photoradiochemical methods to 
include metal ion like In3+ that form complexes with higher coordination numbers.  
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Introduction 
Antibody-based radiotracers are frequently used in Nuclear Medicine for positron-emission 
tomography (PET) imaging.1–5 Such agents facilitate cancer diagnosis and can be used to monitor 
the effectiveness of chemotherapies. Selecting alternative radionuclides like 67Ga and 111In allows 
for the development of radioimmunotherapeutics (RITs).6 Traditional bioconjugation methods that 
are used to modify antibodies and other biomolecules with radionuclides typically require multiple 
chemical steps. First, the biomolecule is purified to remove formulation components that can 
interfere with the chemistry, and then the chelate is conjugated to the protein via standard ligation 
methods (amide, thioester or maleimide thiol couplings to cysteines or lysines etc). In this two-
step conjugation and radiolabelling approach, the conjugated intermediate must also be re-purified 
to remove unreacted chelate that can compromise the radiochemistry. Finally, the chelate-
biomolecule conjugate is radiolabelled, re-purified and characterised before use in vitro or in 
vivo.2–5,7,8 
Photoreactions were employed for bioconjugations.9–11 However, there are only a few 
examples whereby photochemical conjugation was used in the synthesis of radiotracers.12–17, 18-21 
Recently, our group demonstrated that photoradiochemical conjugation methods using different 
photoactive macrocyclic and acyclic chelates suitable for complexation of gallium, copper or 




aryl azide (ArN3) group. Photoradiosynthesis was completed in ~10 min starting directly from 
fully formulated antibody solutions (avoiding pre-purification and buffer exchange of the 
antibody), in high radiochemical yields (up to ~75%), and without compromising the structural 
integrity or biological viability of the protein.18–21 However, a current restriction is that all reported 
photoactive chelates are limited to a maximum of 6 donor atoms which makes them unsuitable for 
coordination chemistry using larger metal ions like In3+ that preferentially form complexes with 
higher coordination numbers. 
Diethylenetriaminepentaacetic acid (DTPA) is a high affinity binder of several metal 
cations. It bears three tertiary amines, and five sterically unconstrained carboxylic acids which can 
coordinate metal ions or be used as functionalisation handles.22,23 The DTPA chelate has been 
wildly used in nuclear chemistry due to the fact that it forms stable coordination compounds with 
various metal ions including, indium24 (formation constant log b = 29.0 – 29.5), yttrium24 (log b = 
21.2 – 22.5), gallium24 (log b = 25.5) and lanthanides like gadolinium25 (log b = 22.46).22,23,26–32 
Several 111In-radiolabelled antibodies that incorporated the DTPA chelate have received clinical 
approval for SPECT imaging. These include 111In-satumomab pendetide for the diagnosis of 
colorectal and ovarian carcinomas33, and 111In-capromab pendetide for prostate cancer therapy.34–
36 
Here, we attached the photoactive aryl azide group to DTPA via the use of a trimeric 
polyethylene glycol (PEG3) spacer to yield DTPA-PEG3-ArN3 (compound 1). This photoactive 
DTPA derivative broadens the metal ion scope of photo-induced conjugation reactions as it readily 
forms complexes with Gd3+ ions for developing magnetic resonance imaging (MRI) agents, 67Ga3+ 
or 111In3+ ions for combination with single-photon emission computed tomography and RIT, and 




kinetics of DTPA-PEG3-ArN3, and the corresponding non-radioactive and radioactive gallium and 
indium complexes, were studied by irradiation with 365 nm light in water. Moreover, the 
efficiency of light-induced conjugation of the photoactive chelate and the radioactive 68Ga- and 
111In-complexes with trastuzumab (anti-human epidermal growth factor receptor 2, human IgG1, 
Genentech, CA) was studied using both a traditional two-step, and a new one-pot 
photoradiochemical process.  
 
Methods and Materials 
Full experimental details and characterisation data for all synthetic steps, radiochemistry and 
photochemical reactions are presented in the Electronic Supporting Information. 
 
Results and Discussion 
Synthesis of DTPA-PEG3-ArN3 and the natGa3+ and natIn3+ complexes 
 
Scheme 1. Synthesis of DTPA-PEG3-ArN3 (1): a) Boc2O, CH2Cl2, 0 °C to rt; b) HATU, DIPEA, DMF, rt; c) TFA, 






DTPA-PEG3-ArN3 (compound 1) was synthesised in five linear steps (Scheme 1) using chemical 
transformations starting from the key reagents 4-azidobenzoic acid, 3,3'-((oxybis(ethane-2,1-
diyl))bis(oxy))bis(propan-1-amine), and 3,6,9-tris(2-(tert-butoxy)-2-oxoethyl)-13,13-dimethyl-
11-oxo-12-oxa-3,6,9-triazatetradecan-1-oic acid (also known as DTPA-(tBu)4 ester). Synthesis 
and full characterisation of the pegylated aryl azide amine (compound 6) was reported 
previously.18 Compound 6 was coupled to the DTPA-(tBu)4 ester using HATU chemistry to give 
the protected intermediate (7) which was deprotected without isolation using trifluoroacetic acid 
to afford compound 1 (DTPA-PEG3-ArN3) in an overall yield of 21%. Compound 1 was 
characterised by reverse-phase high-performance liquid chromatography (HPLC), high-resolution 
electrospray ionisation mass spectrometry (HR-ESI-MS), 1H- and 13C-NMR spectroscopy, and 
electronic absorption spectroscopy (Figures S1-S4).  
 After isolation and characterisation of compound 1, the corresponding natGa3+ and natIn3+ 
complexes were prepared and characterised by HPLC, HR-ESI-MS, and electronic absorption 
spectroscopy (Figures S5-S8). 
 
Photochemical activation kinetics  
 The photochemical properties of compound 1, Ga-1– and In-1– were analysed by irradiating 
aqueous solutions with an ultraviolet, light emitting diode (LED) source with peak emission 
intensity at 364.5 nm (power output ~92 mW, with a full-width at half maximum of 9.1 nm). 
Aliquots of the irradiated solutions were analysed at different time points by HPLC. The three 
compounds showed higher photoreactivity than previously reported photoactive derivatives of 
aza-macrocycles and acyclic desferrioxamine B (DFO) or HBED-CC chelates bearing ArN3 




induced degradation with pseudo-first-order rate constants of 0.078 ± 0.045 s-1, 0.093 ± 0.009 s-1, 
0.117 ± 0.054 s-1 (n = 2 independent replicated per species), respectively (Figure 1). Under the 
irradiation conditions employed, the formation of one major product peak was observed for each 
compound. Mass spectrometry analysis of the irradiated species indicated the formation of the 
corresponding water adducts (Figures S9-S12). 
Figure 1. Photochemical activation kinetics showing the changes in the HPLC chromatograms (panels A – C), and 
the corresponding normalised integration of the peak intensities for starting material and major product for compound 
1, natGa-1– and natIn-1–, respectively (panels D – F). 
 
 
Radiosynthesis and photochemical activity of [68Ga]GaDTPA-PEG3-ArN3 (68Ga-1–) and 
[111In]InDTPA-PEG3-ArN3 (111In-1-) 
 After characterising the non-radioactive species, 68Ga- and 111In-radiolabelling and 




species was prepared by reacting compound 1 with an aliquot of [68Ga][Ga(H2O)6]Cl3(aq.) 
obtained from elution of a 68Ge/68Ga-generator with HCl (0.1 M) using standard radiochemical 
methods. 68Ga-radiolabelling experiments were performed in acetate buffer (0.25 M, pH 4.4) at 
room temperature. 
The radiolabelled 111In-1– species was prepared by reacting compound 1 with an aliquot of 
[111In][InCl3(aq.) dissolved in HCl (0.1 M) (Curium Pharma, Paris, France) using standard 
radiochemical methods. 111In-radiolabelling experiments were performed in acetate buffer (0.25 
M, pH 4.4) at room temperature. 
 A comparison of the electronic absorption (l = 254 nm) and radioactive chromatograms 
revealed that metal ion complexation gave a slight increase in retention on reverse-phase HPLC. 
The identity of the single radioactive peak obtained in the 68Ga- and 111In-radiolabelling reactions 
(Figure 2 (panel A: Ga; panel B: In), red traces) was confirmed by comparison of retention times 
and by standard co-elution (spike) methods using the authentic samples of natGa-1– (Figure 2 A, 
blue trace) and natIn-1– (Figure 2B, blue trace). Upon irradiation, photoactivation of both the Ga-
1– (Figure 2A, green and orange traces) and In-1– (Figure 2B, green and orange traces) complexes 
occurred with complete loss of the peak associated with the starting complexes and formation of 
several new species (with one major product, vide supra) that eluted at shorter retention times. The 
experimental chromatograms are consistent with the photochemical activation kinetics and also 
with the proposed mechanism which primarily leads to the formation more polar intermediates and 
by-products.37 Overall, these radiolabelling experiments confirmed that the compound 1 could be 
radiolabelled efficiently with two different radionuclides, and that photoactivation chemistry of 
the radioactive nat/68Ga-1– and nat/111In-1– complexes was equivalent at the different molar extents 





Figure 2. Normalised high-performance liquid chromatography (HPLC) data showing, a single peak for the elution 
of compound 1 (black), and single peaks observed for non-radioactive complex natGa-1– (A, blue) and natIn-1– (B, 
blue), co-elution of the radioactive species 68Ga-1– (A, red) and 111In-1– (B, red) confirming chemical identity, and the 
electronic absorption (254 nm) and radiochromatograms obtained after irradiating (365 nm, 10 min., 23 oC) natGa-1– 
(A, green) and natIn-1– (B, green), or 68Ga-1– (orange) and 111In-1– (B, orange). 
 
Photochemical conjugation of DTPA-PEG3-ArN3 to trastuzumab 
One-pot approach For our intended purpose of functionalising proteins with drugs, chelates or 
radioactive complexes, increased photochemical reactivity is desirable, but only if it does not 
compromise the efficiency of the desired bimolecular conjugation. Detailed experimental, 
spectrometric and computational work on the mechanism of photochemical activation, 
rearrangement to a ketenimine intermediate, and bimolecular nucleophilic attack by primary 
amines has been reported.18–21 Extreme reactivity of the photo-induced intermediates is one of the 
numerous attractive features of utilising photochemistry to label antibodies but conversely it is 
also one of the main challenges. Specifically, after UV irradiation induces the loss of N2(g) from 




ensure that the reactivity of the electrophilic intermediates favours bimolecular coupling with an 
amine or carboxylate residue on the protein over non-productive intramolecular cyclisation or 
quenching by the background solvent (water). 
Photochemical conjugation and radiolabelling experiments were performed to investigate 
the efficiency of light-induced functionalisation of trastuzumab using either a recently introduced 
one-pot or conventional two-step approach (Scheme 2).  
 
 
Scheme 2. Overview of the one-pot (left) and two-step (right) routes for photochemical conjugation and 68Ga-
radiolabelling of trastuzumab with DTPA-PEG3-ArN3. Note. An equivalent approach can be taken using 111In. 
 
 All photochemical conjugation reactions were performed by irradiating reaction mixtures 
for 15 min. at 23 oC to ensure complete light-induced activation of the starting materials. Typically, 




experience with 68Ga-radiolabelled macrocyclic chelates.18,19 In the one-pot approach, DTPA-
PEG3-ArN3 (1) was dissolved in water, the pH was adjusted to ~4 – 4.5 using sodium acetate 
buffer, and then an appropriate aliquot of 68Ga-chloride (with the activity formerly present as 
solvated [68Ga][Ga(H2O)6]3+, [68Ga][Ga(H2O)5(OH)]2+ or [68Ga][Ga(H2O)4(OH)2]+ ions) or 111In-
chloride was added. The pH of the reaction was adjusted in situ to pH 7.7 – 8.3 using Na2CO3, 
after adding the radioactivity but before the addition of the antibody. Subsequently, the reaction 
mixtures were exposed to UV light. Aliquots of the crude reaction mixture were retained for further 
analysis, and a fraction was purified via standard spin-column centrifugation and solid-phase PD-
10 size-exclusion chromatography (SEC) methods. All samples and appropriate controls were 
analysed by instant thin layer radiochromatography (radio-iTLC), analytical SEC PD-10 methods, 
and SEC radiochromatography. Data for the one-pot radiochemistry using 68Ga are presented in 
Figure 3 and equivalent data using 111In are given in Figure 4). 
 
 
Figure 3. Analytical radiochemical data for the one-pot photoradiosynthesis of [68Ga]GaDTPA-azepin-trastuzumab. 
(A) Radio-iTLC data showing the migration on silica gel strips for ‘free’ 68Ga3+ ions (present as 68Ga-citrate; orange 
control), 68Ga-1– before irradiation (green), the mixture of 68Ga-1– after irradiation in the absence of protein (red), and 
the crude (blue) and purified (black) [68Ga]GaDTPA-azepin-trastuzumab species formed after irradiation in the 
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presence of the antibody. (B) PD-10 size-exclusion elution profiles showing the analysis of the crude (blue) and 
purified (black) [68Ga]GaDTPA-azepin-trastuzumab species. (C) SEC radiochromatography data showing the elution 





Figure 4. Analytical radiochemical data for the one-pot photoradiosynthesis of [111In]InDTPA-azepin-trastuzumab. 
(A) Radio-iTLC data showing the migration on silica gel strips for ‘free’ 111In3+ ions (present as 111In-chloride; orange 
control), 111In-1– before irradiation (green), the mixture of 111In-1– after irradiation in the absence of protein (red), and 
the crude (blue) and purified (black) [111In]InDTPA-azepin-trastuzumab species formed after irradiation in the 
presence of the antibody. (B) PD-10 size-exclusion elution profiles showing the analysis of the crude (blue) and 
purified (black) [111In]InDTPA-azepin-trastuzumab species. (C) SEC radiochromatography data showing the elution 
profiles of 111In-1– after irradiation in the absence of protein (red), the crude (blue) and purified (black) [111In]InDTPA-
azepin-trastuzumab species. 
 
 Under the radio-iTLC conditions used (0.2 M sodium citrate, pH4.5) uncomplexed ‘free’ 
68Ga3+ and 111In3+species reacted with citrate and migrated to the solvent front (Rf = 1.0; Figures 




peak from approximately Rf = 0.25 – 0.60 and 0.15 – 0.35 (Figures 3A and 4A, green trace), 
respectively. Irradiation in the presence of the antibody led to retention of a fraction of the activity 
at the baseline (Rf = 0.0) which is indicative of radiolabelled protein as shown for the crude 
(Figures 3A and 4A, blue trace) and purified (Figures 3A and 4A, black trace) 68Ga- and 111In-
DTPA-azepin-trastuzumab product. However, irradiation of the 68Ga-1– and 111In-1– also gave an 
increase in baseline activity due to the formation of more polar species which were retained on 
silica. Therefore, further confirmation that the radioactivity was bound to the protein, and accurate 
quantification of radiochemical conversions was obtained by analytical SEC PD-10 
chromatography (Figures 3B and 4B) and by SEC radiochromatography (Figure 3C and 4C). For 
the one-pot reactions, an average radiochemical conversion of 3.9 ± 1.0% (n = 4; measured by 
SEC radiochromatography) and 5.4 ± 0.8% (n = 3; measured by SEC radiochromatography) was 
observed for either the 68Ga or the 111In complexes. Radiochemical purities >80% could only be 
obtained after extensive purification of the radiolabelled DTPA-azepin-trastuzumab. Given that an 
initial 10:1 chelate-to-mAb ratio was used, the estimated upper limit to the average number of 68Ga 
or 111In chelates bound per antibody was 0.39 ± 0.1 (n = 4) and 0.54 ± 0.1 (n = 3), respectively. 
We note that the actual chelate-to-mAb ratio in the final product is likely to be lower but accurate 
quantification is non-trivial due to the variations in molar activity and radiochemical purity of the 
68Ga and 111In stock solutions. 
Notably, the purification of 68Ga- and 111In-DTPA-azepin-trastuzumab from the large 
excess of radioactive small molecule species that also formed during the reaction was challenging. 
Crude mixtures were purified by multiple centrifugal filtration cycles using 30 kDa cut-off spin 
filters and also by preparative SEC PD-10. Purified product could be obtained after two cycles of 




encountered in purification is most likely caused by the low radiochemical conversion which 
makes it challenging to isolate the radioactive protein from the impurities (about 90%). Moreover, 
weak ion pair association of the anionic 68Ga-1– and 111In-1– (and related by-products) with cation 
residues (for example, lysine side-chains) on the protein might increase the separation difficulties. 
  
Two-step approach using 68Ga: Given that comparatively low photochemical conjugation 
efficiencies were observed by using the one-pot procedure, we also investigated the efficiency of 
a conventional two-step approach. First, pre-purified trastuzumab (spin filtration, 30 kDa cut-off) 
was photochemically conjugated with DTPA-PEG3-ArN3 using an initial 5:1 or 10:1 chelate-to-
mAb ratio. The reactions were buffered with NaHCO3 (1.0 M) to a pH between 7.9 – 8.3. The 
crude reaction mixtures were purified by preparative PD-10-SEC eluting with PBS. Prior to 
analysis, samples were concentrated centrifugal filtration. Aliquots of the crude and purified 
reaction mixtures were radiolabelled with 68Ga3+ ions to measure the crude radiochemical purity 
(RCP) of [68Ga]GaDTPA-azepin-trastuzumab. Radio-iTLC, PD-10 and SEC 
radiochromatography data are presented in Figure 5. 
 
Figure 5. Analytical radiochemical data for the two-step photochemical conjugation and subsequent radiolabelling to 




[68Ga]GaDTPA-azepin-trastuzumab species formed after irradiation in the presence of the antibody. (B) PD-10 size-
exclusion elution profiles showing the analysis of the crude (blue) and purified (black) [68Ga]GaDTPA-azepin-
trastuzumab species. (C) SEC radiochromatography data showing crude elution profile [68Ga]GaDTPA-azepin-
trastuzumab after the one-pot synthesis (red) and equivalent data for the crude (blue) and purified (black) 
[68Ga]GaDTPA-azepin-trastuzumab species produced via the two-step approach. 
 
The average radiochemical conversion obtained via the two-step process (with an initial 
chelate-to-mAb ratio of 5:1) was 10.0 ± 1.0%, (n = 3). Increasing the chelate-to-mAb ratio to 10:1 
showed only a minor increase in conversion to 12.8%. If one compares these results with the one-
pot reactions with the same chelate-to-mAb ratio (10:1) but a lower protein concentration (53.8 
vs. 89 µM, Table S1, Figure S13) these measured radiochemical conversions support the 
assumption of a first-order reaction with respect to the protein concentration. Since lower chelate-
to-mAb ratios are preferred for antibody functionalisation due to the expense of the reagents, 
higher ratios were not investigated. Notably, the two-step process led to a higher fraction of 
aggregated / dimerised antibody in the final product (highlighted by the asterisk in Figure 5C, 
black trace) when compared to the one-pot reactions with either 68Ga (Figure 3C, black trace) or 
111In (Figure 4C, black trace). In spite of the lower radiochemical conversion obtained via the one-
pot method, reducing the fraction of aggregated protein is a crucial factor in optimising the 
pharmacokinetics and radiation dosimetry of radiolabelled antibodies in vivo.20,34 
Overall, the experimental data confirm that photoactive DTPA-PEG3-ArN3 is a viable tool 
for use in the photoradiosynthesis of functionalised antibodies for the production of diagnostic 
probes or radioimmunotherapeutics.  
 




To investigate the concentration dependency of the photochemical conjugation reaction, 
different protein concentrations were evaluated in conjugation with the one-pot process. The 
conjugation with 111In-1– showed a linear dependency of the conversion with respect to the protein 
concentration (Table S1 and Figure S13). At the lowest protein concentration of 19.7 µM only a 
very low RCY of 3.1 ± 0.1% (n = 2; Table S1 condition A) was obtained. Increasing the 
concentration to 39 µM increased the RCY to 5.4 ± 0.8% (n = 3; Figure S13 entry 2). At higher 
protein concentrations of 53 and 83 µM, radiochemical conversions of 6.9 ± 0.8% (n = 2; Table 
S2 condition B and Figure S13 entry 4) and 8.5 ± 1.8% (n = 2; Table S1 condition C and Figure 
S13 entry 6), respectively, were observed (Table S1). One-pot reactions with the 68Ga-1– complex 
show a similar behaviour with an increase in RCY from 3.9 ± 1.0% (n = 4; Figure S13 entry 3) to 
8.9% (n = 1; Figure S13 entry 5) when the mAb concentration was increased from 38 to 54 µM, 
respectively (Table S1, Figure S13). 
These results provide further evidence to suggest that the photochemically induced 
conjugation reaction is first-order with respect to the protein concentration – as required due to the 
bimolecular nature of the coupling process. These data also indicate that, given the conditions 
employed, the product ratio between radiolabelled mAb and other photolysis by-products is likely 
under kinetic control. Full optimisation of the reaction conditions, and extensive kinetic 
experiments are beyond the scope of the current work but our experiments strongly suggest that a 
detailed understanding of the radiochemical kinetics will facilitate improvements in the efficiency 
of our photoradiosynthetic process.38 
A comparison of the radiochemical conversions from the reaction of various 68Ga-aza-
macrocyclic complexes, 89Zr-radiolabelled DFO-ArN3, and 68Ga-1– and 111In-1– with pre-purified 




using aza-macrocyclic complexes, DTPA-PEG3-ArN3 gave the lowest one-pot radiochemical 
conversion to radiolabelled trastuzumab. Precise reasons as to why the use of compound 1 gave 
lower radiochemical conversions remain unknown. However, given that one-pot reactions using 
68Ga-1– and 111In-1– complexes showed similar radiochemical conversions (3.9 ± 1.0% and 5.4 ± 
0.8%, respectively), it seems plausible that kinetics, in the form of parallel reactions between 
productive mAb functionalisation and background quenching, is the limiting factor. Another 
potential reasons for the low radiochemical conversion observed could be the increased 
photochemical activation kinetics of compound 1, nat/68Ga-1– and nat/111In-1– (Figure 1) compared 
with equivalent measurements using other ligand systems (Table 1). There is also the possibility 
that the initial photolysis products undergo further photoactivated transformations (secondary 
photolysis) which would complicate the process. Further synthetic, spectroscopic and kinetic 
experiments are underway to investigate structure-activity relationships in more detail and to 
elucidate the nature of the competing side reactions that currently impose empirical limits on the 
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18.5 ± 0.5% (n = 2) c Fay et al. 21 
Table 1. Comparison of the radiochemical conversions (as a percentage) obtained from the reaction of various 68Ga- 
and 89Zr-radiolabelled photoactive chelates with pre-purified antibodies.18–21 
a Errors reported as one standard deviation from the mean. b One-pot photoradiolabelling using trastuzumab. c Two-
step photoradiolabelling using onartuzumab. 
 
Conclusions  
The photoactive DTPA-PEG3-ArN3 (1) was synthesised, and characterised by using a range of 
chemical, spectroscopic, photochemical, kinetic and radiochemical methods. Non-radioactive 
experiments confirmed that the natGa3+ and natIn3+ complexes remained photochemically active 
with rapid photoactivation kinetics. 68Ga- and 111In-radiolabelling experiments confirmed that the 




radioactive complex exhibited equivalent photoactivity to the non-radioactive natGa and natIn 
complexes. Photochemical conjugation to pre-purified trastuzumab was successful and the 
radiolabelled 68Ga- and 111In-DTPA-azepin-trastuzumab product were obtained in comparatively 
low radiochemical conversions via either a one-pot or a classical two-step radiosynthetic 
procedure. Although the conjugation efficiency was lower than other reported photoactive 
complexes, access to DTPA-PEG3-ArN3 expands the potential chemical scope and utility of 
photo(radio)synthesis since the acyclic DTPA-chelate can accommodate larger metal ions (such 
as 111In3+ or natGd3+) for future use in SPECT imaging, radioimmunotherapy or the development 
of targeted contrast agents for MRI. 
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Photoradiosynthesis was used to functionalise proteins with chelates for imaging and therapy. The 
DTPA-PEG3-ArN3 ligand and the corresponding Ga3+ and In3+ complexes were synthesised and 
photoactivation experiments with ultraviolet light (365 nm) showed fast reaction kinetics. 
Photochemically induced bioconjugation reactions between 68Ga- or 111In-radiolabelled DTPA-
PEG3-ArN3 and trastuzumab showed conversions between 4 and 12%. The use of DTPA expands 
the scope of photochemical conjugation methods to include metal ions like In3+ and potentially 
lanthanides. 
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